Final report of the OLYMPUS Jelmyto trial: Takeaways for urologists

Video

“I think that these data firmly establish UGN-101, or Jelmyto, as a bona fide treatment option for kidney preservation for patients with low-grade, non-invasive urothelial cancer in the upper urinary tract,” says Seth P. Lerner, MD.

In this video, Seth P. Lerner, MD, gives the final results of the phase 3 OLYMPUS trial, which studied the efficacy of mitomycin-containing reverse thermal gel (UGN-101; Jelmyto) in patients with upper tract urothelial carcinoma and supported the FDA approval of the treatment in this setting.

Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.

Related Videos
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Heather L. Huelster, MD, answers a question during a Zoom video interview
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Bottle of white pills | Image Credit: © leighannef - stock.adobe.com
Illustration of AI | Image Credit: © Tierney - stock.adobe.com
DNA illustration | Image Credit: © BillionPhotos.com - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.